Table 1 Clinicopathologic manifestations of 441 nipple-sparing mastectomy procedures enrolled in current study
n = 441 | Mean (sd), n (%) |
|---|---|
Age, y | 49.1 ± 9.8 |
BMI | |
< 27 | 384 (87.1) |
≥ 27 | 57 (12.9) |
Location | |
Left | 219 (49.7) |
Right | 222 (50.3) |
Surgery type | |
Convention | 106 (24.0) |
Endoscopy | 242 (54.9) |
Robot | 93 (21.1) |
Reconstruction | |
Yes | 369 (83.7) |
No | 72 (16.3) |
Reconstruction method (n = 369) | |
Tissue expander | 9 (2.4) |
Gel implant | 321 (87.0) |
TRAM flap | 33 (8.9) |
LD flap + gel implant | 2 (0.5) |
LD flap | 4 (1.1) |
Type of skin incisions (N/A = 1) | |
Upper outer oblique incisions | 83 (18.9) |
Peri-areolar incisions | 107 (24.3) |
Single axillary incisions | 243 (55.2) |
Infra-mammary + axillary incisions | 7 (1.6) |
Pathology tumor size, cm | 2.6 ± 2.3 |
Grade (N/A = 102) | |
I | 65 (19.2) |
II | 204 (60.2) |
III | 70 (20.6) |
Clinical stage (N/A = 132) | |
0 | 76 (24.6) |
I | 59 (19.1) |
II | 161 (52.1) |
III | 13 (4.2) |
Subtype (N/A = 113) | |
Luminal A | 152 (46.3) |
Luminal B1 | 81 (24.7) |
Luminal B2 | 40 (12.2) |
HER-2 (+) | 26 (7.9) |
TNBC | 29 (8.8) |
Lymph node stage (N/A = 61) | |
N0 | 271 (71.3) |
N1 | 84 (22.1) |
N2 | 22 (5.8) |
N3 | 3 (0.8) |
Surgical ALN staging method (N/A = 129) | |
ALND | 24 (6.4) |
SLNB | 281 (74.7) |
SLNB+ALND | 71 (18.9) |
Lymph node metastasis (N/A = 61) | |
Yes | 109 (28.8) |
No | 270 (71.2) |
Stage (N/A = 80) | |
0 | 82 (22.7) |
I | 95 (26.3) |
II | 151 (41.8) |
III | 33 (9.1) |
ER (N/A = 86) | |
Positive | 289 (81.4) |
Negative | 66 (18.6) |
PR (N/A = 89) | |
Positive | 246 (69.9) |
Negative | 106 (30.1) |
HER-2 (N/A = 134) | |
Positive | 83 (27.0) |
Negative | 224 (73.0) |
Ki-67 (%) (N/A = 181) | |
≦ 14 | 103 (39.6) |
> 14 | 157 (60.4) |
Pathology (N/A = 11) | |
DCIS | 85 (19.8) |
IDC | 239 (55.6) |
ILC | 14 (3.3) |
LCIS | 4 (0.9) |
Other | 88 (20.5) |
NAC ischemia necrosis | |
0 | 371 (84.1) |
1 | 29 (6.6) |
2 | 37 (8.4) |
3 | 4 (0.9) |
Skin flap necrosis | |
0 | 417 (94.6) |
1 | 22 (5.0) |
2 | 2 (0.5) |